ANIK
Anika Therapeutics Inc
20.40$
+0.7%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 71.7% | 74.8% | 70.9% | 73.0% | 72.7% | 70.8% | 48.5% | 48.5% | 48.6% | 60.3% | 56.1% | 54.3% | |
| 51.6% | 47.0% | 43.4% | 47.2% | 31.9% | 47.6% | 26.2% | 27.2% | 24.7% | 25.4% | 27.4% | 30.2% | |
| 55.1% | 58.7% | 51.9% | 55.6% | 57.0% | 55.9% | 26.9% | 27.2% | 24.7% | 25.4% | 27.4% | 30.2% | |
| 8.8% | 9.2% | 11.5% | 8.4% | 7.4% | 7.0% | 6.6% | 8.6% | 9.9% | 9.7% | 11.6% | 12.5% | |
| 6.4% | 6.3% | 6.7% | 7.8% | 7.6% | 6.7% | 12.6% | 10.4% | 11.4% | 9.0% | 11.7% | 9.9% | |
| 16.3% | 17.0% | 21.8% | 19.9% | 19.4% | 15.4% | 13.8% | 13.7% | 13.8% | – | – | – | |
| 4.3% | 3.2% | 3.0% | 2.9% | 2.8% | 2.3% | 2.3% | 2.2% | 2.1% | 2.8% | 3.5% | 4.2% | |
| 7.7% | 4.9% | 4.3% | 3.8% | 3.3% | 2.3% | 24.9% | 23.7% | 21.4% | 1.0% | 1.2% | 0.9% | |
| 8.2% | 10.6% | 7.3% | 6.8% | 5.5% | 12.8% | 25.5% | 17.4% | 18.2% | 21.6% | 24.0% | 24.6% | |
| 3.1% | 7.3% | 3.7% | 4.6% | 4.0% | 4.9% | 10.1% | 8.6% | 8.0% | 11.5% | 11.5% | 11.5% | |
| – | 0.0% | 0.0% | – | – | 0.3% | 0.4% | 0.5% | 0.6% | 0.7% | 0.9% | 1.1% | |
| 0.6% | 3.5% | 1.0% | 2.4% | 1.1% | 1.2% | 2.5% | 2.2% | 2.6% | 2.3% | 2.8% | 3.2% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 91.8% | 89.4% | 92.7% | 93.2% | 94.5% | 87.2% | 74.5% | 82.6% | 81.8% | 78.4% | 76.0% | 75.4% | |
| 54.1% | 57.5% | 70.0% | 70.6% | 78.2% | 74.2% | 60.6% | 64.9% | 60.4% | 47.3% | 35.3% | 31.9% | |
| 7.9% | 6.5% | 6.3% | 5.3% | 5.3% | 4.3% | 3.9% | 4.2% | 4.2% | 5.4% | 7.3% | 7.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.